Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Swiss company...

    Swiss company Actelion moves US court against Natco Pharma over generic of its patented drug

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-06-05T12:27:28+05:30  |  Updated On 13 Aug 2021 4:45 PM IST

    Hyderabad: Swiss pharma company Actelion Pharmaceuticals Ltd has filed a petition in a US court alleging that Natco Pharma and its US partner Syneos Health LLC are attempting to come out with a generic version of its patented drug Tracleer (Bosentan) tablets for oral suspension (dispersible tablets) of 32 mg.


    In the petition on May 28, Actelion alleged that the Indian drugmakers proposed generic Bosentan 32 mg will infringe upon the patent and requested the court to pass an injunction order against manufacturing, importing and selling that drug in the USA.


    Bosentan is a prescription medicine used to treat pulmonary arterial hypertension (PAH, high blood pressure in the vessels that carry blood to the lungs) in adults and children of three years of age and older.


    The US arm of Actelion urged the US court to grant a preliminary and permanent injunction enjoining the defendants, their officers, partners, agents, servants, employees, parents, subsidiaries, affiliate corporations and other business entities from making, using, selling, offering to sell, marketing, distributing, or importing into the United States the Natcos copycat version of Bosentan 32 mg, before the expiry of the patent.


    Read Also: Natco Pharma files ANDA for generic version of Bosentan tablets for oral suspension

    It also sought damages or other monetary relief, including pre-judgment and post-judgment interest, if the defendants engage in the commercial manufacture, use, sale, offer to sell, marketing distribution, or import of the proposed generic version of Bosentan 32 mg, before the expiry of the patent.


    Actelion Pharmaceuticals is the lawful owner with all right, title and interest of the Tracleer (Bosentan) tablets for oral suspension (dispersible tablets) of 32 mg, the petition said.


    On April 16, Natco Ltd had informed the plaintiff that it had submitted to the FDA the Abbreviated New Drug Application(ANDA) for Bostenan tablets for oral suspension of 32 mg, the petition said.


    Actelion is part of the Janssen Pharmaceutical Companies of Johnson & Johnson.


    Under paragraph IV Patent Certifications, a company can seek FDA approval to market a generic drug before the expiry of patents related to the brand-name drug that the generic seeks to copy.


    According to pharma analysts, patent infringement cases are not uncommon for generic drugmakers in USA and the lawsuit would not have any implications on the performance of the company.


    Abbreviated New Drug ApplicationActelion PharmaceuticalsANDABosentan tabletsFDAgeneric druggeneric versionhigh blood pressureJanssen PharmaceuticalJohnson & JohnsonNatco pharmaPAHpatented drug TracleerPulmonary arterial hypertensionSyneos Health LLCUnited StatesUS courtUSA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok